Evaluating Safety and Biological Effect on Wound Healing of ILP100-Topical in Subjects With Diabetic Foot Ulcers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-26

Study Completion Date

2024-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, double-blind, placebo-controlled, parallel, exploratory phase 2a study to evaluate safety and biologic efficacy on wound healing of ILP100-Topical in subjects with diabetic foot ulcers during 26 weeks with a 5-year long-term follow-up period. A total of 30 subjects will be randomized to low dose of ILP100-Topical (ILP100Lo), high dose of ILP100-Topical (ILP100Hi) or Placebo according to a 1:1:1 randomization schedule.

The study will consist of a 3-weeks Screening and Run-in Phase, followed by a 5-week Treatment Phase starting from Baseline and an Assessment Phase from Week 5 to Week 26. Thereafter, the subjects will be followed yearly during 5 years in a Long-Term Safety Follow-up Phase.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Evaluation of Nonhealing Diabetic Foot Ulcers With Exclusive Wound Therapy

NCT07086443

Diabetic Foot Ulcer DFU Diabetic Foot Ulcer (DFU) +4 more

RECRUITING PHASE4

EPC Silver Wound Gel (EPC-123) Feasibility Study in the Management of Mildly Infected Diabetic Foot Ulcers

NCT05243810

Diabetic Foot Ulcer Non-healing Diabetic Foot Ulcer Diabetic Foot Infection

COMPLETED NA

Phase 2b Study of GAM501 in the Treatment of Diabetic Ulcers of the Lower Extremities

NCT00493051

Diabetic Foot

COMPLETED PHASE2

A Phase 2a Proof of Concept Open-Label, Randomized, Controlled Study to Evaluate the Safety and Efficacy of MDI-1228-mesylate Gel Compared With Standard of Care Alone in Patients With Diabetic Foot Ulcers

NCT06852976

Diabetic Foot Ulcer

RECRUITING PHASE2

Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers

NCT00740922

Platelet-Derived Growth Factor Diabetic Foot Neoplasms

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wound Heal Wound Healing Disturbance of Wound Healing Disorder Wound Healing Delayed Diabetic Foot Ulcer Diabetic Foot Ulcer Mixed

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

This is a double-blind study, and the allocation of treatments will not be disclosed to subjects, Investigator or Independent Evaluators until database lock after all subjects (who were not withdrawn) completed Week 26.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ILP100Lo

During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Lo (ILP100-Topical, 5x10\^7 colony forming units (CFU)/cm\^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.

Group Type EXPERIMENTAL

ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2

Intervention Type BIOLOGICAL

Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.

ILP100Hi

During the Treatment Phase, subjects will continue on standard of care according to the protocol and ILP100Hi (ILP100-Topical, 1x10\^9 CFU/cm\^2) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.

Group Type EXPERIMENTAL

ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2

Intervention Type BIOLOGICAL

Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.

Placebo

During the Treatment Phase, subjects will continue on standard of care according to the protocol and Placebo (ILP100 dilution buffer mixed with the activation peptide SppIP) will be topically administered at two occasions on Day 1 (Baseline and Hour 2), Days 2, 3, and thereafter every second to third day until Day 31.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2

Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 5x10\^7 CFU/cm\^2 wound area.

Intervention Type BIOLOGICAL

ILP100-Topical (emilimogene sigulactibac) 1x10^9 CFU/cm^2

Topical application of ILP100-Topical (emilimogene sigulactibac) at a dose of 1x10\^9 CFU/cm\^2 wound area.

Intervention Type BIOLOGICAL

Placebo

Topical application of placebo (ILP100 dilution buffer mixed with the activation peptide SppIP).

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ILP100-Topical ILP100-Topical

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed written informed consent
* Males and females aged ≥18 years
* Diagnosis of diabetes mellitus type 1 or 2
* HbA1c ≤ 86 mmol/mol (≤ 10%) at Screening
* Subjects with at least one first time or recurrent full thickness ulcer (at or below the ankle) which fulfils all of the following criteria at Screening and at the time of Baseline:

1. A non-interdigital wound
2. Accessible for administration of IMP, wound study assessments and procedures
3. Persistence of the wound for at least 6 weeks at Baseline
4. Assessed by the investigator to be of non-venous etiology.
5. Minimum full skin ulcer without undermining, with no exposed muscle, tendon or bone
6. A wound area of 1.0 - 5.0 cm\^2 after sharp or mechanical debridement at Screening
7. During the 2-weeks between start of Run-in Phase and Baseline the wound size must not decrease by more than 30% or increase by more than 25%, which correspond to wound areas of 0.7 - 6.3 cm\^2, or at Screening expected by the Investigator to have a high probability for wound size changes within this range during this period.
* Toe pressure ≥20 mm Hg
* Expected to comply with the study procedures

Exclusion Criteria

* Infected index wound with clinical signs of inflammation at Screening or Baseline.
* The index wound determined as heavily exuding defined as requiring more than 1 dressing change per day or requiring use of super absorbent dressing
* Wound duration longer than 2 years
* Active Charcot deformity of the study foot
* Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2
* Hemoglobin concentration \<100 g/L at Baseline
* Planned or ongoing treatment with corticosteroids to an equivalent dose of prednisolone \>10 mg per day or other immunosuppressive therapy, or such treatment within 4 weeks prior to Baseline
* Has any major surgery or hospitalization planned up to Week 26
* Has changed a treatment for diabetes during the last 3 weeks before Baseline. Dose change is allowed
* Ongoing treatment with dipeptidyl peptidase 4 (DPP-4) inhibitors
* Revascularization procedure in the index wound leg planned or undertaken within 8 weeks before Screening, or under investigation
* Current smokers
* Participation in other clinical studies or having received any investigational treatment within 1 month or at the earliest five times the half-life prior to Screening
* Has any disease conditions, including ulcerative dermatological disorders and vasculitis, or comorbidities which is expected to prevent the subject from participating in the study or confounding the evaluation of the safety profile and effect on wound healing of ILP100
* Pregnant or lactating woman
* Male subjects not willing to use a condom and refrain from donating sperm
* Female subjects of childbearing potential unless they use a contraceptive method with a failure rate of \< 1% to prevent pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No